Initial experience with tadalafil in pediatric pulmonary arterial hypertension

Pediatric Cardiology

Volumn 33, Issue 5, 2012, Pages 683-688

  Takatsuki, Shinichi ^a   Calderbank, Michelle ^a   Ivy, David Dunbar ^a  

^a Children's Hospital Colorado   (United States)

Author keywords

Children; Phosphodiesterase type 5 inhibitor; Safety; Sildenafil; Tadalafil; Tolerability

Indexed keywords

AMBRISENTAN; PROSTACYCLIN; SILDENAFIL; TADALAFIL; UNIPROST;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DRUG EFFECT; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUSHING; HEADACHE; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MIGRAINE; MYALGIA; NAUSEA; NOSE CONGESTION; PRESCHOOL CHILD; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; THORAX PAIN; VEIN CATHETERIZATION;

ADOLESCENT; CARBOLINES; CARDIAC OUTPUT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SULFONES; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 84863980719     PISSN: 01720643     EISSN: 14321971     Source Type: Journal    
DOI: 10.1007/s00246-012-0180-4     Document Type: Article

References (17)

1. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119-2125
2. Chin KM, Rubin LJ (2008) Pulmonary arterial hypertension. J Am Coll Cardiol 51:1527-1538
3. Eli Lilly and Company. ADCIRCA (tadalafil) tablets for oral administration: U.S. prescribing information. Retrieved Oct 2009 at http://www.drugs.com/newdrugs/fda-approves-adcirca-tadalafilpulmonary- arterial-hypertension-1366.html
4. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G(2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148-2157
5. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M (2006) Bosentan therapy in patients with eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.Circulation 114:48-54
6. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119:2894-2903
7. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I (2005) Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study.Circulation 111:3274-3280
8. Ivy DD, Claussen L, Doran A (2007) Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol 99:696-698
9. Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ, Brady D, Law Y, Parker D, Claussen L, Abman SH (2008) Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 51:161-169
10. Ivy DD, Rosenzweig EB, Lemarie JC, Brand M, Rosenberg D, Barst RJ (2010) Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol 106:1332-1338
11. Levy M, Celermajer DS, Bourges-Petit E, Del Cerro MJ, Bajolle F, Bonnet D (2011) Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. J Pediatr 158:584-588
12. Mukhopadhyay S, Sharma M, Ramakrishnan S, Yusuf J, Gupta MD, Bhamri N, Trehan V, Tyagi S (2006) Phosphodiesterase-5 inhibitor in eisenmenger syndrome: a preliminary observational study. Circulation 114:1807-1810
13. Rosenzweig EB (2010) Tadalafil for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 11:127-132
14. Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336:111-117
15. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R (2006) A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 151(851):e851-e855
16. von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, Lockhart D, Beasley CM Jr, Emmick JT (2004) A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 45:499-507 discussion 507-499
17. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ (2004) Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110:660-665